Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 233

1.

Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial.

Quinn JF, Raman R, Thomas RG, Yurko-Mauro K, Nelson EB, Van Dyck C, Galvin JE, Emond J, Jack CR Jr, Weiner M, Shinto L, Aisen PS.

JAMA. 2010 Nov 3;304(17):1903-11. doi: 10.1001/jama.2010.1510.

2.

High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial.

Aisen PS, Schneider LS, Sano M, Diaz-Arrastia R, van Dyck CH, Weiner MF, Bottiglieri T, Jin S, Stokes KT, Thomas RG, Thal LJ; Alzheimer Disease Cooperative Study..

JAMA. 2008 Oct 15;300(15):1774-83. doi: 10.1001/jama.300.15.1774.

3.

Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial.

Freund-Levi Y, Eriksdotter-Jönhagen M, Cederholm T, Basun H, Faxén-Irving G, Garlind A, Vedin I, Vessby B, Wahlund LO, Palmblad J.

Arch Neurol. 2006 Oct;63(10):1402-8.

PMID:
17030655
4.

Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.

Wilcock GK, Black SE, Hendrix SB, Zavitz KH, Swabb EA, Laughlin MA; Tarenflurbil Phase II Study investigators..

Lancet Neurol. 2008 Jun;7(6):483-93. doi: 10.1016/S1474-4422(08)70090-5. Epub 2008 Apr 29. Erratum in: Lancet Neurol. 2011 Apr;10(4):297. Lancet Neurol. 2008 Jul;7(7):575.

PMID:
18450517
5.

Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial.

Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, Farlow MR, Jin S, Thomas RG, Thal LJ; Alzheimer's Disease Cooperative Study..

JAMA. 2003 Jun 4;289(21):2819-26.

PMID:
12783912
6.

Effects of n-3 fatty acids on cognitive decline: a randomized, double-blind, placebo-controlled trial in stable myocardial infarction patients.

Geleijnse JM, Giltay EJ, Kromhout D.

Alzheimers Dement. 2012 Jul;8(4):278-87. doi: 10.1016/j.jalz.2011.06.002. Epub 2011 Oct 2.

PMID:
21967845
7.

Ginkgo biloba for preventing cognitive decline in older adults: a randomized trial.

Snitz BE, O'Meara ES, Carlson MC, Arnold AM, Ives DG, Rapp SR, Saxton J, Lopez OL, Dunn LO, Sink KM, DeKosky ST; Ginkgo Evaluation of Memory (GEM) Study Investigators..

JAMA. 2009 Dec 23;302(24):2663-70. doi: 10.1001/jama.2009.1913.

8.

A randomized controlled study on effects of ibuprofen on cognitive progression of Alzheimer's disease.

Pasqualetti P, Bonomini C, Dal Forno G, Paulon L, Sinforiani E, Marra C, Zanetti O, Rossini PM.

Aging Clin Exp Res. 2009 Apr;21(2):102-10.

PMID:
19448381
9.

Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial.

Green RC, Schneider LS, Amato DA, Beelen AP, Wilcock G, Swabb EA, Zavitz KH; Tarenflurbil Phase 3 Study Group..

JAMA. 2009 Dec 16;302(23):2557-64. doi: 10.1001/jama.2009.1866.

10.

Folic acid with or without vitamin B12 for cognition and dementia.

Malouf M, Grimley EJ, Areosa SA.

Cochrane Database Syst Rev. 2003;(4):CD004514. Review. Update in: Cochrane Database Syst Rev. 2008;(4):CD004514.

PMID:
14584018
12.

Age and rate of cognitive decline in Alzheimer disease: implications for clinical trials.

Bernick C, Cummings J, Raman R, Sun X, Aisen P.

Arch Neurol. 2012 Jul;69(7):901-5.

PMID:
22431834
13.

Effect of tramiprosate in patients with mild-to-moderate Alzheimer's disease: exploratory analyses of the MRI sub-group of the Alphase study.

Gauthier S, Aisen PS, Ferris SH, Saumier D, Duong A, Haine D, Garceau D, Suhy J, Oh J, Lau W, Sampalis J.

J Nutr Health Aging. 2009 Jun;13(6):550-7. Erratum in: J Nutr Health Aging. 2010 Jan;14(1):80.

PMID:
19536424
14.

Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial.

Smith AD, Smith SM, de Jager CA, Whitbread P, Johnston C, Agacinski G, Oulhaj A, Bradley KM, Jacoby R, Refsum H.

PLoS One. 2010 Sep 8;5(9):e12244. doi: 10.1371/journal.pone.0012244.

15.

Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline.

Yurko-Mauro K, McCarthy D, Rom D, Nelson EB, Ryan AS, Blackwell A, Salem N Jr, Stedman M; MIDAS Investigators..

Alzheimers Dement. 2010 Nov;6(6):456-64. doi: 10.1016/j.jalz.2010.01.013.

16.

Cognitive and cardiovascular benefits of docosahexaenoic acid in aging and cognitive decline.

Yurko-Mauro K.

Curr Alzheimer Res. 2010 May;7(3):190-6. Review.

PMID:
20088810
17.

Four-year placebo-controlled trial of docosahexaenoic acid in X-linked retinitis pigmentosa (DHAX trial): a randomized clinical trial.

Hoffman DR, Hughbanks-Wheaton DK, Pearson NS, Fish GE, Spencer R, Takacs A, Klein M, Locke KG, Birch DG.

JAMA Ophthalmol. 2014 Jul;132(7):866-73. doi: 10.1001/jamaophthalmol.2014.1634.

19.

Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial.

Wilkinson D, Windfeld K, Colding-Jørgensen E.

Lancet Neurol. 2014 Nov;13(11):1092-9. doi: 10.1016/S1474-4422(14)70198-X. Epub 2014 Oct 5.

PMID:
25297016
20.

Omega-3 fatty acids for the treatment of dementia.

Burckhardt M, Herke M, Wustmann T, Watzke S, Langer G, Fink A.

Cochrane Database Syst Rev. 2016 Apr 11;4:CD009002. doi: 10.1002/14651858.CD009002.pub3. Review.

PMID:
27063583

Supplemental Content

Support Center